1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Efficacy and safety evaluation of type‐3 phosphodiesterase inhibitor Cilostazol in mild cognitive impairment

      abstract
      1 , , 1 , 2 , 1 , the COMCID Trial Investigator Group
      Alzheimer's & Dementia
      John Wiley and Sons Inc.

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Cilostazol, a selective type‐3 phosphodiesterase inhibitor, ameliorates β‐amyloid accumulation by facilitating intramural periarterial drainage.

          Method

          Patients with mild cognitive impairment were registered in the COMCID study, an investigator‐initiated, double‐blinded, multi‐center, phase‐II clinical trial. The primary endpoint was the Mini‐Mental State Examination score. Several psychological assessments and circulating β‐amyloid‐albumin complex levels were evaluated as secondary and exploratory endpoints.

          Result

          Patients were randomly allocated to the Cilostazol (n = 82) or placebo (n = 84) group. There were no serious adverse events caused by the drug intervention. The primary and secondary efficacy endpoints were not different between the two groups. A significant negative correlation between the blood levels of β‐amyloid‐albumin complexes at baseline and the 24‐week visit was observed in the Cilostazol group ( P = .005) but not in the placebo group ( P = .336).

          Conclusion

          Cilostazol was well‐tolerated and may have facilitated β‐amyloid clearance from the brain to the blood but did not prevent cognitive decline.

          Related collections

          Author and article information

          Contributors
          saitou.satoshi.43m@kyoto-u.jp
          Journal
          Alzheimers Dement
          Alzheimers Dement
          10.1002/(ISSN)1552-5279
          ALZ
          Alzheimer's & Dementia
          John Wiley and Sons Inc. (Hoboken )
          1552-5260
          1552-5279
          09 January 2025
          December 2024
          : 20
          : Suppl 6 ( doiID: 10.1002/alz.v20.S6 )
          : e086323
          Affiliations
          [ 1 ] National Cerebral and Cardiovascular Center, Suita, Osaka Japan
          [ 2 ] Foundation of Learning Health Society Institute, Nagoya, Aichi Japan
          Author notes
          [*] [* ] Correspondence

          Satoshi Saito, National Cerebral and Cardiovascular Center, Suita, Osaka, Japan.

          Email: saitou.satoshi.43m@ 123456kyoto-u.jp

          Article
          ALZ086323
          10.1002/alz.086323
          11712677
          a4df057d-393b-4371-89f8-4f67b93485bf
          © 2024 The Alzheimer's Association. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.

          This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

          History
          Page count
          Figures: 0, Tables: 0, Pages: 1, Words: 289
          Categories
          Drug Development
          Drug Development
          Podium Presentation
          Custom metadata
          2.0
          December 2024
          Converter:WILEY_ML3GV2_TO_JATSPMC version:6.5.2 mode:remove_FC converted:09.01.2025

          Comments

          Comment on this article